 | • レポートコード：QY20ST-09295 • 出版社/出版日：QYResearch / 2020年9月15日 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、139ページ • 納品方法：Eメール（受注後2~3営業日） • 産業分類：医薬品、医療 |
| Single User | ￥560,000 (USD4,000) | ▷ お問い合わせ |
| Multi User | ￥840,000 (USD6,000) | ▷ お問い合わせ |
| Enterprise License | ￥1,120,000 (USD8,000) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートでは、世界の未分化リンパ腫キナーゼ阻害剤市場について種類別（クリゾチニブ、セリチニブ、塩酸アレクチニブ）、用途別（NSCLC、 Breast Cancer、 Colorectal Cancer、 Neuroblastoma、 Ovarian Cancer、 Others）、地域別（北米、ヨーロッパ、中国、日本、東南アジア、インド）に区分して調査し、纏めました。2015年～2026年までの市場規模予測、主要プレイヤーの競争状況・市場シェア・企業情報、製造コスト分析、販売チャネル・流通業者・顧客情報、市場動向・機会・課題などのマーケットデータが記載されています。市場予測データは新型コロナウイルスの影響を反映させました。 ・未分化リンパ腫キナーゼ阻害剤市場の概要 ・世界の主要地域別未分化リンパ腫キナーゼ阻害剤市場規模2015-2026 ・主要プレイヤーの競争状況・市場シェア ・世界の未分化リンパ腫キナーゼ阻害剤市場規模2015-2026：種類別（クリゾチニブ、セリチニブ、塩酸アレクチニブ） ・世界の未分化リンパ腫キナーゼ阻害剤市場規模2015-2026：用途別（NSCLC、 Breast Cancer、 Colorectal Cancer、 Neuroblastoma、 Ovarian Cancer、 Others） ・未分化リンパ腫キナーゼ阻害剤の北米市場規模2015-2020 ・未分化リンパ腫キナーゼ阻害剤のヨーロッパ市場規模2015-2020 ・未分化リンパ腫キナーゼ阻害剤の中国市場規模2015-2020 ・未分化リンパ腫キナーゼ阻害剤の日本市場規模2015-2020 ・未分化リンパ腫キナーゼ阻害剤の東南アジア市場規模2015-2020 ・未分化リンパ腫キナーゼ阻害剤のインド市場規模2015-2020 ・主要プレイヤーの企業情報：事業概要・売上・企業動向 ・未分化リンパ腫キナーゼ阻害剤の製造コスト分析 ・販売チャネル、流通業者、顧客 ・未分化リンパ腫キナーゼ阻害剤の市場動向・機会・課題 ・調査の結論 |
A recently published report by QY Research titled Global Anaplastic Lymphoma Kinase Inhibitors Sales Market Report 2020 is designed in a way that helps the readers to acquire a complete knowledge about the overall market scenario and it’s most lucrative sectors. The research report also statistically provides accurate data in a statistical manner. It examines the historic accomplishments and recent opportunities present in the global Anaplastic Lymphoma Kinase Inhibitors market. QY Research report focuses on the consumption, geography, by type, by application, and the competitive landscape. The 4000 version of the report mainly splits the data for each region to analyze the leading companies, applications, and product types.
QY Research aims to provide a complete knowledgeable report so that the readers will benefit from it. The report is properly examined and compiled by industry experts and will shed light on the key information that requires from the clients.
Report Overview:
ALK inhibitors are potential anti-cancer drugs that act on tumours with variations of anaplastic lymphoma kinase (ALK) such as an EML4-ALK translocation.[
Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost 100 countries around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Anaplastic Lymphoma Kinase Inhibitors market in 2020.
COVID-19 can affect the global economy in three main ways: by directly affecting production and demand, by creating supply chain and market disruption, and by its financial impact on firms and financial markets.
The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.
This report also analyses the impact of Coronavirus COVID-19 on the Anaplastic Lymphoma Kinase Inhibitors industry.
Based on our recent survey, we have several different scenarios about the Anaplastic Lymphoma Kinase Inhibitors YoY growth rate for 2020. The probable scenario is expected to grow by a xx% in 2020 and the revenue will be xx in 2020 from US$ xx million in 2019. The market size of Anaplastic Lymphoma Kinase Inhibitors will reach xx in 2026, with a CAGR of xx% from 2020 to 2026.
QY Research report provides an overview and scope of the global Anaplastic Lymphoma Kinase Inhibitors market, stating its drivers, trends, opportunities, and restraints. The report also comprises all key details of the global Anaplastic Lymphoma Kinase Inhibitors market such as market strategies, sales volumes, and consumption. The report also covers the names of all distribution channels such as manufacturers, suppliers, wholesalers, distributors, consumers, and dealers.
QY Research also presents the statistical data in the form of infographics, tables, and charts to predict the trends and developments of the global Anaplastic Lymphoma Kinase Inhibitors market over the forecast period. The research analysts have also used a framework such as key industry experts interview, research papers, refer journals, survey reports, and face-to-face interviews with expert professionals to know the detailed outlook of the global Anaplastic Lymphoma Kinase Inhibitors market. The report also includes nautical information, where it shows Anaplastic Lymphoma Kinase Inhibitors market product volume, utilization value, and production processes.
The research report also consists of a competitive landscape that describes the top players that are functioning in the global Anaplastic Lymphoma Kinase Inhibitors market. This report also describes the key developments and trends, mergers and acquisitions strategies, and new product innovation that will show an enormous benefit to the companies that are competing in the global Anaplastic Lymphoma Kinase Inhibitors market.
Geographical Analysis:
Based on region, the global Anaplastic Lymphoma Kinase Inhibitors market is segmented into North America, Europe, China, Japan, Southeast Asia India and Other regions (Middle East & Africa, Central & South America). Research analysts have studied government initiatives, changing the political environment, and social scenarios that are likely to contribute to the growth of the regional markets.
Key Players:
The major players that are operating in the global Anaplastic Lymphoma Kinase Inhibitors market are
Betta Pharmaceutcials Co., Ltd.
Crtierium, Inc.
F.Hoffman-La Roche Ltd.
Helsinn Therapeutics
Novartis AG.
Oncoethix GmbH
Pfizer, Inc.
Takeda Pharmaceutical Co., Ltd.
Xcovery Holding Company, LLC
Tesaro, Inc.
Segment by Type
Crizotinib
Ceritinib
Alectinib Hydrochloride
Segment by Application
NSCLC
Breast Cancer
Colorectal Cancer
Neuroblastoma
Ovarian Cancer
Others
Competitive Landscape:
Factors such as cost analysis, marketing strategy, factor analysis, distributors, sourcing strategy, and industrial chain are all the parts of the global Anaplastic Lymphoma Kinase Inhibitors market. The report also includes the analysis of the return on investment (ROI) feasibility with the estimated SWOT analysis.
The report covers the following objectives:
• Proliferation and maturation of trade in the global Anaplastic Lymphoma Kinase Inhibitors market.
• The market share of the global Anaplastic Lymphoma Kinase Inhibitors market, supply and demand ratio, growth revenue, supply chain analysis, and business overview.
• Current and future market trends that are influencing the growth opportunities and growth rate of the global Anaplastic Lymphoma Kinase Inhibitors market.
• Feasibility study, new market insights, company profiles, investment return, revenue (value), and consumption (volume) of the global Anaplastic Lymphoma Kinase Inhibitors market.
1 Anaplastic Lymphoma Kinase Inhibitors Market Overview
1.1 Anaplastic Lymphoma Kinase Inhibitors Product Scope
1.2 Anaplastic Lymphoma Kinase Inhibitors Segment by Type
1.2.1 Global Anaplastic Lymphoma Kinase Inhibitors Sales by Type (2020-2026)
1.2.2 Crizotinib
1.2.3 Ceritinib
1.2.4 Alectinib Hydrochloride
1.3 Anaplastic Lymphoma Kinase Inhibitors Segment by Application
1.3.1 Global Anaplastic Lymphoma Kinase Inhibitors Sales Comparison by Application (2020-2026)
1.3.2 NSCLC
1.3.3 Breast Cancer
1.3.4 Colorectal Cancer
1.3.5 Neuroblastoma
1.3.6 Ovarian Cancer
1.3.7 Others
1.4 Anaplastic Lymphoma Kinase Inhibitors Market Estimates and Forecasts (2015-2026)
1.4.1 Global Anaplastic Lymphoma Kinase Inhibitors Sales Growth Rate (2015-2026)
1.4.2 Global Anaplastic Lymphoma Kinase Inhibitors Revenue and Growth Rate (2015-2026)
1.4.3 Global Anaplastic Lymphoma Kinase Inhibitors Price Trends (2015-2026)
1.5 Coronavirus Disease 2019 (Covid-19): Anaplastic Lymphoma Kinase Inhibitors Industry Impact
1.5.1 How the Covid-19 is Affecting the Anaplastic Lymphoma Kinase Inhibitors Industry
1.5.1.1 Anaplastic Lymphoma Kinase Inhibitors Business Impact Assessment – Covid-19
1.5.1.2 Supply Chain Challenges
1.5.1.3 COVID-19’s Impact On Crude Oil and Refined Products
1.5.2 Market Trends and Anaplastic Lymphoma Kinase Inhibitors Potential Opportunities in the COVID-19 Landscape
1.5.3 Measures / Proposal against Covid-19
1.5.3.1 Government Measures to Combat Covid-19 Impact
1.5.3.2 Proposal for Anaplastic Lymphoma Kinase Inhibitors Players to Combat Covid-19 Impact
2 Anaplastic Lymphoma Kinase Inhibitors Estimate and Forecast by Region
2.1 Global Anaplastic Lymphoma Kinase Inhibitors Market Size by Region: 2015 VS 2020 VS 2026
2.2 Global Anaplastic Lymphoma Kinase Inhibitors Retrospective Market Scenario by Region (2015-2020)
2.2.1 Global Anaplastic Lymphoma Kinase Inhibitors Sales Market Share by Region (2015-2020)
2.2.2 Global Anaplastic Lymphoma Kinase Inhibitors Revenue Market Share by Region (2015-2020)
2.3 Global Anaplastic Lymphoma Kinase Inhibitors Market Estimates and Forecasts by Region (2021-2026)
2.3.1 Global Anaplastic Lymphoma Kinase Inhibitors Sales Estimates and Forecasts by Region (2021-2026)
2.3.2 Global Anaplastic Lymphoma Kinase Inhibitors Revenue Forecast by Region (2021-2026)
2.4 Geographic Market Analysis: Market Facts & Figures
2.4.1 United States Anaplastic Lymphoma Kinase Inhibitors Estimates and Projections (2015-2026)
2.4.2 Europe Anaplastic Lymphoma Kinase Inhibitors Estimates and Projections (2015-2026)
2.4.3 China Anaplastic Lymphoma Kinase Inhibitors Estimates and Projections (2015-2026)
2.4.4 Japan Anaplastic Lymphoma Kinase Inhibitors Estimates and Projections (2015-2026)
2.4.5 Southeast Asia Anaplastic Lymphoma Kinase Inhibitors Estimates and Projections (2015-2026)
2.4.6 India Anaplastic Lymphoma Kinase Inhibitors Estimates and Projections (2015-2026)
3 Global Anaplastic Lymphoma Kinase Inhibitors Competition Landscape by Players
3.1 Global Top Anaplastic Lymphoma Kinase Inhibitors Players by Sales (2015-2020)
3.2 Global Top Anaplastic Lymphoma Kinase Inhibitors Players by Revenue (2015-2020)
3.3 Global Anaplastic Lymphoma Kinase Inhibitors Market Share by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Anaplastic Lymphoma Kinase Inhibitors as of 2019)
3.4 Global Anaplastic Lymphoma Kinase Inhibitors Average Price by Company (2015-2020)
3.5 Manufacturers Anaplastic Lymphoma Kinase Inhibitors Manufacturing Sites, Area Served, Product Type
3.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3.7 Primary Interviews with Key Anaplastic Lymphoma Kinase Inhibitors Players (Opinion Leaders)
4 Global Anaplastic Lymphoma Kinase Inhibitors Market Size by Type
4.1 Global Anaplastic Lymphoma Kinase Inhibitors Historic Market Review by Type (2015-2020)
4.1.1 Global Anaplastic Lymphoma Kinase Inhibitors Sales Market Share by Type (2015-2020)
4.1.2 Global Anaplastic Lymphoma Kinase Inhibitors Revenue Market Share by Type (2015-2020)
4.1.3 Global Anaplastic Lymphoma Kinase Inhibitors Price by Type (2014-2020)
4.2 Global Anaplastic Lymphoma Kinase Inhibitors Market Estimates and Forecasts by Type (2021-2026)
4.2.1 Global Anaplastic Lymphoma Kinase Inhibitors Sales Forecast by Type (2021-2026)
4.2.2 Global Anaplastic Lymphoma Kinase Inhibitors Revenue Forecast by Type (2021-2026)
4.2.3 Global Anaplastic Lymphoma Kinase Inhibitors Price Forecast by Type (2021-2026)
5 Global Anaplastic Lymphoma Kinase Inhibitors Market Size by Application
5.1 Global Anaplastic Lymphoma Kinase Inhibitors Historic Market Review by Application (2015-2020)
5.1.1 Global Anaplastic Lymphoma Kinase Inhibitors Sales Market Share by Application (2015-2020)
5.1.2 Global Anaplastic Lymphoma Kinase Inhibitors Revenue Market Share by Application (2015-2020)
5.1.3 Global Anaplastic Lymphoma Kinase Inhibitors Price by Application (2015-2020)
5.2 Global Anaplastic Lymphoma Kinase Inhibitors Market Estimates and Forecasts by Application (2021-2026)
5.2.1 Global Anaplastic Lymphoma Kinase Inhibitors Sales Forecast by Application (2021-2026)
5.2.2 Global Anaplastic Lymphoma Kinase Inhibitors Revenue Forecast by Application (2021-2026)
5.2.3 Global Anaplastic Lymphoma Kinase Inhibitors Price Forecast by Application (2021-2026)
3 North America Anaplastic Lymphoma Kinase Inhibitors Market Facts & Figures
3.2 North America Anaplastic Lymphoma Kinase Inhibitors Sales Market Share by Company (2015-2020)
3.3 North America Anaplastic Lymphoma Kinase Inhibitors Sales Market Share by Type (2015-2020)
3.4 North America Anaplastic Lymphoma Kinase Inhibitors Sales Market Share by Application (2015-2020)
4 Europe Anaplastic Lymphoma Kinase Inhibitors Market Facts & Figures
4.2 Europe Anaplastic Lymphoma Kinase Inhibitors Sales Market Share by Company (2015-2020)
4.3 Europe Anaplastic Lymphoma Kinase Inhibitors Sales Market Share by Type (2015-2020)
4.4 Europe Anaplastic Lymphoma Kinase Inhibitors Sales Market Share by Application (2015-2020)
5 China Anaplastic Lymphoma Kinase Inhibitors Market Facts & Figures
5.2 China Anaplastic Lymphoma Kinase Inhibitors Sales Market Share by Company (2015-2020)
5.3 China Anaplastic Lymphoma Kinase Inhibitors Sales Market Share by Type (2015-2020)
5.4 China Anaplastic Lymphoma Kinase Inhibitors Sales Market Share by Application (2015-2020)
6 Japan Anaplastic Lymphoma Kinase Inhibitors Market Facts & Figures
6.2 Japan Anaplastic Lymphoma Kinase Inhibitors Sales Market Share by Company (2015-2020)
6.3 Japan Anaplastic Lymphoma Kinase Inhibitors Sales Market Share by Type (2015-2020)
6.4 Japan Anaplastic Lymphoma Kinase Inhibitors Sales Market Share by Application (2015-2020)
7 Southeast Asia Anaplastic Lymphoma Kinase Inhibitors Market Facts & Figures
7.2 Southeast Asia Anaplastic Lymphoma Kinase Inhibitors Sales Market Share by Company (2015-2020)
7.3 Southeast Asia Anaplastic Lymphoma Kinase Inhibitors Sales Market Share by Type (2015-2020)
7.4 Southeast Asia Anaplastic Lymphoma Kinase Inhibitors Sales Market Share by Application (2015-2020)
8 India Anaplastic Lymphoma Kinase Inhibitors Market Facts & Figures
8.2 India Anaplastic Lymphoma Kinase Inhibitors Sales Market Share by Company (2015-2020)
8.3 India Anaplastic Lymphoma Kinase Inhibitors Sales Market Share by Type (2015-2020)
8.4 India Anaplastic Lymphoma Kinase Inhibitors Sales Market Share by Application (2015-2020)
12 Company Profiles and Key Figures in Anaplastic Lymphoma Kinase Inhibitors Business
12.1 Betta Pharmaceutcials Co., Ltd.
12.1.1 Betta Pharmaceutcials Co., Ltd. Anaplastic Lymphoma Kinase Inhibitors Corporation Information
12.1.2 Betta Pharmaceutcials Co., Ltd. Anaplastic Lymphoma Kinase Inhibitors Business Overview and Total Revenue
12.1.3 Betta Pharmaceutcials Co., Ltd. Anaplastic Lymphoma Kinase Inhibitors Sales, Revenue and Gross Margin (2015-2020)
12.1.4 Betta Pharmaceutcials Co., Ltd. Anaplastic Lymphoma Kinase Inhibitors Products Offered
12.1.5 Betta Pharmaceutcials Co., Ltd. Recent Development
12.2 Crtierium, Inc.
12.2.1 Crtierium, Inc. Anaplastic Lymphoma Kinase Inhibitors Corporation Information
12.2.2 Crtierium, Inc. Anaplastic Lymphoma Kinase Inhibitors Business Overview and Total Revenue
12.2.3 Crtierium, Inc. Anaplastic Lymphoma Kinase Inhibitors Sales, Revenue and Gross Margin (2015-2020)
12.2.4 Crtierium, Inc. Anaplastic Lymphoma Kinase Inhibitors Products Offered
12.2.5 Crtierium, Inc. Recent Development
12.3 F.Hoffman-La Roche Ltd.
12.3.1 F.Hoffman-La Roche Ltd. Anaplastic Lymphoma Kinase Inhibitors Corporation Information
12.3.2 F.Hoffman-La Roche Ltd. Anaplastic Lymphoma Kinase Inhibitors Business Overview and Total Revenue
12.3.3 F.Hoffman-La Roche Ltd. Anaplastic Lymphoma Kinase Inhibitors Sales, Revenue and Gross Margin (2015-2020)
12.3.4 F.Hoffman-La Roche Ltd. Anaplastic Lymphoma Kinase Inhibitors Products Offered
12.3.5 F.Hoffman-La Roche Ltd. Recent Development
12.4 Helsinn Therapeutics
12.4.1 Helsinn Therapeutics Anaplastic Lymphoma Kinase Inhibitors Corporation Information
12.4.2 Helsinn Therapeutics Anaplastic Lymphoma Kinase Inhibitors Business Overview and Total Revenue
12.4.3 Helsinn Therapeutics Anaplastic Lymphoma Kinase Inhibitors Sales, Revenue and Gross Margin (2015-2020)
12.4.4 Helsinn Therapeutics Anaplastic Lymphoma Kinase Inhibitors Products Offered
12.4.5 Helsinn Therapeutics Recent Development
12.5 Novartis AG.
12.5.1 Novartis AG. Anaplastic Lymphoma Kinase Inhibitors Corporation Information
12.5.2 Novartis AG. Anaplastic Lymphoma Kinase Inhibitors Business Overview and Total Revenue
12.5.3 Novartis AG. Anaplastic Lymphoma Kinase Inhibitors Sales, Revenue and Gross Margin (2015-2020)
12.5.4 Novartis AG. Anaplastic Lymphoma Kinase Inhibitors Products Offered
12.5.5 Novartis AG. Recent Development
12.6 Oncoethix GmbH
12.6.1 Oncoethix GmbH Anaplastic Lymphoma Kinase Inhibitors Corporation Information
12.6.2 Oncoethix GmbH Anaplastic Lymphoma Kinase Inhibitors Business Overview and Total Revenue
12.6.3 Oncoethix GmbH Anaplastic Lymphoma Kinase Inhibitors Sales, Revenue and Gross Margin (2015-2020)
12.6.4 Oncoethix GmbH Anaplastic Lymphoma Kinase Inhibitors Products Offered
12.6.5 Oncoethix GmbH Recent Development
12.7 Pfizer, Inc.
12.7.1 Pfizer, Inc. Anaplastic Lymphoma Kinase Inhibitors Corporation Information
12.7.2 Pfizer, Inc. Anaplastic Lymphoma Kinase Inhibitors Business Overview and Total Revenue
12.7.3 Pfizer, Inc. Anaplastic Lymphoma Kinase Inhibitors Sales, Revenue and Gross Margin (2015-2020)
12.7.4 Pfizer, Inc. Anaplastic Lymphoma Kinase Inhibitors Products Offered
12.7.5 Pfizer, Inc. Recent Development
12.8 Takeda Pharmaceutical Co., Ltd.
12.8.1 Takeda Pharmaceutical Co., Ltd. Anaplastic Lymphoma Kinase Inhibitors Corporation Information
12.8.2 Takeda Pharmaceutical Co., Ltd. Anaplastic Lymphoma Kinase Inhibitors Business Overview and Total Revenue
12.8.3 Takeda Pharmaceutical Co., Ltd. Anaplastic Lymphoma Kinase Inhibitors Sales, Revenue and Gross Margin (2015-2020)
12.8.4 Takeda Pharmaceutical Co., Ltd. Anaplastic Lymphoma Kinase Inhibitors Products Offered
12.8.5 Takeda Pharmaceutical Co., Ltd. Recent Development
12.9 Xcovery Holding Company, LLC
12.9.1 Xcovery Holding Company, LLC Anaplastic Lymphoma Kinase Inhibitors Corporation Information
12.9.2 Xcovery Holding Company, LLC Anaplastic Lymphoma Kinase Inhibitors Business Overview and Total Revenue
12.9.3 Xcovery Holding Company, LLC Anaplastic Lymphoma Kinase Inhibitors Sales, Revenue and Gross Margin (2015-2020)
12.9.4 Xcovery Holding Company, LLC Anaplastic Lymphoma Kinase Inhibitors Products Offered
12.9.5 Xcovery Holding Company, LLC Recent Development
12.10 Tesaro, Inc.
12.10.1 Tesaro, Inc. Anaplastic Lymphoma Kinase Inhibitors Corporation Information
12.10.2 Tesaro, Inc. Anaplastic Lymphoma Kinase Inhibitors Business Overview and Total Revenue
12.10.3 Tesaro, Inc. Anaplastic Lymphoma Kinase Inhibitors Sales, Revenue and Gross Margin (2015-2020)
12.10.4 Tesaro, Inc. Anaplastic Lymphoma Kinase Inhibitors Products Offered
12.10.5 Tesaro, Inc. Recent Development
13 Anaplastic Lymphoma Kinase Inhibitors Manufacturing Cost Analysis
13.1 Anaplastic Lymphoma Kinase Inhibitors Key Raw Materials Analysis
13.1.1 Key Raw Materials
13.1.2 Key Raw Materials Price Trend
13.1.3 Key Suppliers of Raw Materials
13.2 Proportion of Manufacturing Cost Structure
13.3 Manufacturing Process Analysis of Anaplastic Lymphoma Kinase Inhibitors
13.4 Anaplastic Lymphoma Kinase Inhibitors Industrial Chain Analysis
14 Marketing Channel, Distributors and Customers
14.1 Marketing Channel
14.2 Anaplastic Lymphoma Kinase Inhibitors Distributors List
14.3 Anaplastic Lymphoma Kinase Inhibitors Customers
15 Market Dynamics
15.1 Market Trends
15.2 Opportunities and Drivers
15.3 Challenges
15.4 Porter’s Five Forces Analysis
16 Research Findings and Conclusion
17 Appendix
17.1 Research Methodology
17.1.1 Methodology/Research Approach
17.1.2 Data Source
17.2 Author List
17.3 Disclaimer
Table 1. Global Anaplastic Lymphoma Kinase Inhibitors Sales (MT) Growth Rate by Type (2020-2026)
Table 2. Global Anaplastic Lymphoma Kinase Inhibitors Sales (MT) Comparison by Application (2020-2026)
Table 3. COVID-19 Impact Global Market: (Four Anaplastic Lymphoma Kinase Inhibitors Market Size Forecast Scenarios)
Table 4. Opportunities and Trends for Anaplastic Lymphoma Kinase Inhibitors Players in the COVID-19 Landscape
Table 5. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis
Table 6. Key Regions/Countries Measures against Covid-19 Impact
Table 7. Proposal for Anaplastic Lymphoma Kinase Inhibitors Players to Combat Covid-19 Impact
Table 8. Global Market Anaplastic Lymphoma Kinase Inhibitors Market Size (US$ Million) by Region:2015 VS 2020 &2026
Table 9. Global Anaplastic Lymphoma Kinase Inhibitors Sales (MT) by Region (2015-2020)
Table 10. Global Anaplastic Lymphoma Kinase Inhibitors Sales Market Share by Region (2015-2020)
Table 11. Global Anaplastic Lymphoma Kinase Inhibitors Revenue (US$ Million) Market Share by Region (2015-2020))
Table 12. Global Anaplastic Lymphoma Kinase Inhibitors Revenue Share by Region (2015-2020)
Table 13. Global Anaplastic Lymphoma Kinase Inhibitors Sales (MT) Forecast by Region (2021-2026)
Table 14. Global Anaplastic Lymphoma Kinase Inhibitors Sales Market Share Forecast by Region (2021-2026)
Table 15. Global Anaplastic Lymphoma Kinase Inhibitors Revenue (US$ Million) Forecast by Region (2021-2026)
Table 16. Global Anaplastic Lymphoma Kinase Inhibitors Revenue Share Forecast by Region (2021-2026)
Table 17. Global Anaplastic Lymphoma Kinase Inhibitors (MT) of Key Companies (2015-2020)
Table 18. Global Anaplastic Lymphoma Kinase Inhibitors Sales Share by Company (2015-2020)
Table 19. Global Anaplastic Lymphoma Kinase Inhibitors Revenue (US$ Million) by Company (2015-2020)
Table 20. Global Anaplastic Lymphoma Kinase Inhibitors Revenue Share by Company (2015-2020)
Table 21. Global Anaplastic Lymphoma Kinase Inhibitors by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Anaplastic Lymphoma Kinase Inhibitors as of 2019)
Table 22. Global Anaplastic Lymphoma Kinase Inhibitors Average Price (USD/MT) of Key Company (2015-2020)
Table 23. Manufacturers Anaplastic Lymphoma Kinase Inhibitors Manufacturing Sites and Area Served
Table 24. Manufacturers Anaplastic Lymphoma Kinase Inhibitors Product Type
Table 25. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 26. Main Points Interviewed from Key Anaplastic Lymphoma Kinase Inhibitors Players
Table 27. Global Anaplastic Lymphoma Kinase Inhibitors Sales (MT) by Type (2015-2020)
Table 28. Global Anaplastic Lymphoma Kinase Inhibitors Sales Share by Type (2015-2020)
Table 29. Global Anaplastic Lymphoma Kinase Inhibitors Revenue (US$ Million) Market Share by Type (2015-2020)
Table 30. Global Anaplastic Lymphoma Kinase Inhibitors Price (MT) by Type (2015-2020)
Table 31. Global Anaplastic Lymphoma Kinase Inhibitors Sales Share by Type (2021-2026)
Table 32. Global Anaplastic Lymphoma Kinase Inhibitors Revenue (US$ Million) Market Share by Type (2021-2026)
Table 33. Global Anaplastic Lymphoma Kinase Inhibitors Revenue Share by Type (2021-2026)
Table 34. Global Anaplastic Lymphoma Kinase Inhibitors Price (MT) by Type (2021-2026)
Table 35. Global Anaplastic Lymphoma Kinase Inhibitors Sales (MT) by Application (2015-2020)
Table 36. Global Anaplastic Lymphoma Kinase Inhibitors Sales Share by Application (2015-2020)
Table 37. Global Anaplastic Lymphoma Kinase Inhibitors Revenue (US$ Million) Market Share by Application (2015-2020)
Table 38. Global Anaplastic Lymphoma Kinase Inhibitors Price (MT) by Application (2015-2020)
Table 39. Global Anaplastic Lymphoma Kinase Inhibitors Sales (MT) by Application (2021-2026)
Table 40. Global Anaplastic Lymphoma Kinase Inhibitors Sales Share by Application (2021-2026)
Table 41. Global Anaplastic Lymphoma Kinase Inhibitors Revenue (US$ Million) Market Share by Application (2021-2026)
Table 42. Global Anaplastic Lymphoma Kinase Inhibitors Revenue Share by Application (2021-2026)
Table 43. Global Anaplastic Lymphoma Kinase Inhibitors Price (MT) by Application (2021-2026)
Table 44. United States Anaplastic Lymphoma Kinase Inhibitors Sales (MT) by Company (2015-2020)
Table 45. United States Anaplastic Lymphoma Kinase Inhibitors Sales Market Share by Company (2015-2020)
Table 46. United States Anaplastic Lymphoma Kinase Inhibitors Sales (MT) by Type (2015-2020)
Table 47. United States Anaplastic Lymphoma Kinase Inhibitors Sales Market Share by Type (2015-2020)
Table 48. United States Anaplastic Lymphoma Kinase Inhibitors Sales (MT) by Application (2015-2020)
Table 49. United States Anaplastic Lymphoma Kinase Inhibitors Sales Market Share by Application (2015-2020)
Table 50. Europe Anaplastic Lymphoma Kinase Inhibitors Sales (MT) by Company (2015-2020)
Table 51. Europe Anaplastic Lymphoma Kinase Inhibitors Sales Market Share by Company (2015-2020)
Table 52. Europe Anaplastic Lymphoma Kinase Inhibitors Sales (MT) by Type (2015-2020)
Table 53. Europe Anaplastic Lymphoma Kinase Inhibitors Sales Market Share by Type (2015-2020)
Table 54. Europe Anaplastic Lymphoma Kinase Inhibitors Sales (MT) by Application (2015-2020)
Table 55. Europe Anaplastic Lymphoma Kinase Inhibitors Sales Market Share by Type (2015-2020)
Table 56. China Anaplastic Lymphoma Kinase Inhibitors Sales (MT) by Company (2015-2020)
Table 57. China Anaplastic Lymphoma Kinase Inhibitors Sales Market Share by Company (2015-2020)
Table 58. China Anaplastic Lymphoma Kinase Inhibitors Sales (MT) by Type (2015-2020)
Table 59. China Anaplastic Lymphoma Kinase Inhibitors Sales Market Share by Type (2015-2020)
Table 60. China Anaplastic Lymphoma Kinase Inhibitors Sales (MT) by Application (2015-2020)
Table 61. China Anaplastic Lymphoma Kinase Inhibitors Sales Market Share by Application (2015-2020)
Table 62. Japan Anaplastic Lymphoma Kinase Inhibitors Sales (MT) by Company (2015-2020)
Table 63. Japan Anaplastic Lymphoma Kinase Inhibitors Sales Market Share by Company (2015-2020)
Table 64. Japan Anaplastic Lymphoma Kinase Inhibitors Sales (MT) by Type (2015-2020)
Table 65. Japan Anaplastic Lymphoma Kinase Inhibitors Sales Market Share by Type (2015-2020)
Table 66. Japan Anaplastic Lymphoma Kinase Inhibitors Sales (MT) by Application (2015-2020)
Table 67. Japan Anaplastic Lymphoma Kinase Inhibitors Sales Market Share by Application (2015-2020)
Table 68. Southeast Asia Anaplastic Lymphoma Kinase Inhibitors Sales (MT) by Company (2015-2020)
Table 69. Southeast Asia Anaplastic Lymphoma Kinase Inhibitors Sales Market Share by Company (2015-2020)
Table 70. Southeast Asia Anaplastic Lymphoma Kinase Inhibitors Sales (MT) by Type (2015-2020)
Table 71. Southeast Asia Anaplastic Lymphoma Kinase Inhibitors Sales Market Share by Type (2015-2020)
Table 72. Southeast Asia Anaplastic Lymphoma Kinase Inhibitors Sales (MT) by Type (2015-2020)
Table 73. Southeast Asia Anaplastic Lymphoma Kinase Inhibitors Sales Market Share by Application (2015-2020)
Table 74. India Anaplastic Lymphoma Kinase Inhibitors Sales (MT) by Company (2015-2020)
Table 75. India Anaplastic Lymphoma Kinase Inhibitors Sales Market Share by Company (2015-2020)
Table 76. India Anaplastic Lymphoma Kinase Inhibitors Sales (MT) by Type (2015-2020)
Table 77. India Anaplastic Lymphoma Kinase Inhibitors Sales Market Share by Type (2015-2020)
Table 78. India Anaplastic Lymphoma Kinase Inhibitors Sales (MT) by Application (2015-2020)
Table 79. India Anaplastic Lymphoma Kinase Inhibitors Sales Market Share by Application (2015-2020)
Table 80. Betta Pharmaceutcials Co., Ltd. Corporation Information
Table 81. Betta Pharmaceutcials Co., Ltd. Description and Business Overview
Table 82. Betta Pharmaceutcials Co., Ltd. Anaplastic Lymphoma Kinase Inhibitors Sales (MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2015-2020)
Table 83. Betta Pharmaceutcials Co., Ltd. Anaplastic Lymphoma Kinase Inhibitors Product
Table 84. Betta Pharmaceutcials Co., Ltd. Recent Development
Table 85. Crtierium, Inc. Corporation Information
Table 86. Crtierium, Inc. Description and Business Overview
Table 87. Crtierium, Inc. Anaplastic Lymphoma Kinase Inhibitors Sales (MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2015-2020)
Table 88. Crtierium, Inc. Anaplastic Lymphoma Kinase Inhibitors Product
Table 89. Crtierium, Inc. Recent Development
Table 90. F.Hoffman-La Roche Ltd. Corporation Information
Table 91. F.Hoffman-La Roche Ltd. Description and Business Overview
Table 92. F.Hoffman-La Roche Ltd. Anaplastic Lymphoma Kinase Inhibitors Sales (MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2015-2020)
Table 93. F.Hoffman-La Roche Ltd. Anaplastic Lymphoma Kinase Inhibitors Product
Table 94. F.Hoffman-La Roche Ltd. Recent Development
Table 95. Helsinn Therapeutics Corporation Information
Table 96. Helsinn Therapeutics Description and Business Overview
Table 97. Helsinn Therapeutics Anaplastic Lymphoma Kinase Inhibitors Sales (MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2015-2020)
Table 98. Helsinn Therapeutics Anaplastic Lymphoma Kinase Inhibitors Product
Table 99. Helsinn Therapeutics Recent Development
Table 100. Novartis AG. Corporation Information
Table 101. Novartis AG. Description and Business Overview
Table 102. Novartis AG. Anaplastic Lymphoma Kinase Inhibitors Sales (MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2015-2020)
Table 103. Novartis AG. Anaplastic Lymphoma Kinase Inhibitors Product
Table 104. Novartis AG. Recent Development
Table 105. Oncoethix GmbH Corporation Information
Table 106. Oncoethix GmbH Description and Business Overview
Table 107. Oncoethix GmbH Anaplastic Lymphoma Kinase Inhibitors Sales (MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2015-2020)
Table 108. Oncoethix GmbH Anaplastic Lymphoma Kinase Inhibitors Product
Table 109. Oncoethix GmbH Recent Development
Table 110. Pfizer, Inc. Corporation Information
Table 111. Pfizer, Inc. Description and Business Overview
Table 112. Pfizer, Inc. Anaplastic Lymphoma Kinase Inhibitors Sales (MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2015-2020)
Table 113. Pfizer, Inc. Anaplastic Lymphoma Kinase Inhibitors Product
Table 114. Pfizer, Inc. Recent Development
Table 115. Takeda Pharmaceutical Co., Ltd. Corporation Information
Table 116. Takeda Pharmaceutical Co., Ltd. Anaplastic Lymphoma Kinase Inhibitors Sales (MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2015-2020)
Table 117. Takeda Pharmaceutical Co., Ltd. Description and Business Overview
Table 118. Takeda Pharmaceutical Co., Ltd. Anaplastic Lymphoma Kinase Inhibitors Product
Table 119. Takeda Pharmaceutical Co., Ltd. Recent Development
Table 120. Xcovery Holding Company, LLC Corporation Information
Table 121. Xcovery Holding Company, LLC Anaplastic Lymphoma Kinase Inhibitors Sales (MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2015-2020)
Table 122. Xcovery Holding Company, LLC Description and Business Overview
Table 123. Xcovery Holding Company, LLC Anaplastic Lymphoma Kinase Inhibitors Product
Table 124. Xcovery Holding Company, LLC Recent Development
Table . Tesaro, Inc. Corporation Information
Table . Tesaro, Inc. Description and Business Overview
Table . Tesaro, Inc. Anaplastic Lymphoma Kinase Inhibitors Sales (MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2015-2020)
Table . Tesaro, Inc. Anaplastic Lymphoma Kinase Inhibitors Product
Table . Tesaro, Inc. Recent Development
Table 130. Production Base and Market Concentration Rate of Raw Material
Table 131. Key Suppliers of Raw Materials
Table 132. Anaplastic Lymphoma Kinase Inhibitors Distributors List
Table 133. Anaplastic Lymphoma Kinase Inhibitors Customers List
Table 134. Market Key Trends
Table 135. Key Opportunities and Drivers: Impact Analysis (2020-2026)
Table 136. Key Challenges
Table 137. Research Programs/Design for This Report
Table 138. Key Data Information from Secondary Sources
Table 139. Key Data Information from Primary Sources
List of Figures
Figure 1. Anaplastic Lymphoma Kinase Inhibitors Product Picture
Figure 2. Global Anaplastic Lymphoma Kinase Inhibitors Sales Market Share by Type in 2020 & 2026
Figure 3. Type I Product Picture
Figure 4. Type II Product Picture
Figure 5. Global Anaplastic Lymphoma Kinase Inhibitors Market Share by Application in 2020 & 2026
Figure 6. NSCLC Examples
Figure 7. Breast Cancer Examples
Figure 8. Colorectal Cancer Examples
Figure 9. Neuroblastoma Examples
Figure 10. Ovarian Cancer Examples
Figure 11. Others Examples
Figure 12. Global Anaplastic Lymphoma Kinase Inhibitors Sales (MT) Growth Rate (2015-2026)
Figure 13. Global Anaplastic Lymphoma Kinase Inhibitors Revenue (US$ Million) Growth Rate (2015-2026)
Figure 14. Global Anaplastic Lymphoma Kinase Inhibitors Price Trends Growth Rate (2015-2026) (USD/MT)
Figure 15. Global Anaplastic Lymphoma Kinase Inhibitors Revenue Market Share by Region: 2015 VS 2020
Figure 16. Global Anaplastic Lymphoma Kinase Inhibitors Revenue Market Share by Region: 2021 VS 2026
Figure 17. United States Anaplastic Lymphoma Kinase Inhibitors Revenue (Million USD) Growth Rate (2015-2026)
Figure 18. United States Anaplastic Lymphoma Kinase Inhibitors Sales (MT) Growth Rate (2015-2026)
Figure 19. Europe Anaplastic Lymphoma Kinase Inhibitors Revenue (Million USD) Growth Rate (2015-2026)
Figure 20. Europe Anaplastic Lymphoma Kinase Inhibitors Sales (Million USD) Growth Rate (2015-2026)
Figure 21. China Anaplastic Lymphoma Kinase Inhibitors Revenue (Million USD) Growth Rate (2015-2026)
Figure 22. China Anaplastic Lymphoma Kinase Inhibitors Sales (Million USD) and Growth Rate (2015-2026)
Figure 23. Japan Anaplastic Lymphoma Kinase Inhibitors Revenue (Million USD) Growth Rate (2015-2026)
Figure 24. Japan Anaplastic Lymphoma Kinase Inhibitors Sales (Million USD) Growth Rate (2015-2026)
Figure 25. Southeast Asia Anaplastic Lymphoma Kinase Inhibitors Revenue (Million USD) Growth Rate (2015-2026)
Figure 26. Southeast Asia Anaplastic Lymphoma Kinase Inhibitors Sales (Million USD) Growth Rate (2015-2026)
Figure 27. India Anaplastic Lymphoma Kinase Inhibitors Revenue (Million USD) Growth Rate (2015-2026)
Figure 28. India Anaplastic Lymphoma Kinase Inhibitors Sales (Million USD) Growth Rate (2015-2026)
Figure 29. Global 5 Largest Anaplastic Lymphoma Kinase Inhibitors Players Market Share by Revenue in Anaplastic Lymphoma Kinase Inhibitors 2015 & 2019
Figure 30. Anaplastic Lymphoma Kinase Inhibitors Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 31. Global Anaplastic Lymphoma Kinase Inhibitors Revenue Share by Type (2015-2020)
Figure 32. Global Anaplastic Lymphoma Kinase Inhibitors Revenue Growth Rate by Type in 2015 & 2019
Figure 33. Global Anaplastic Lymphoma Kinase Inhibitors Revenue Share by Application (2015-2020)
Figure 34. Global Anaplastic Lymphoma Kinase Inhibitors Revenue Growth Rate by Application in 2015 & 2019
Figure 35. United States Anaplastic Lymphoma Kinase Inhibitors Sales Market Share by Type in 2019
Figure 36. United States Anaplastic Lymphoma Kinase Inhibitors Sales Market Share by Type in 2019
Figure 37. Europe Anaplastic Lymphoma Kinase Inhibitors Sales Market Share by Company in 2019
Figure 38. Europe Anaplastic Lymphoma Kinase Inhibitors Sales Market Share by Type in 2019
Figure 39. Europe Anaplastic Lymphoma Kinase Inhibitors Sales Market Share by Application in 2019
Figure 40. China Anaplastic Lymphoma Kinase Inhibitors Sales Market Share by Company in 2019
Figure 41. China Anaplastic Lymphoma Kinase Inhibitors Sales Market Share by Type in 2019
Figure 42. China Anaplastic Lymphoma Kinase Inhibitors Sales Market Share by Application in 2019
Figure 43. Japan Anaplastic Lymphoma Kinase Inhibitors Sales Market Share by Company in 2019
Figure 44. Japan Anaplastic Lymphoma Kinase Inhibitors Sales Market Share by Type in 2019
Figure 45. Japan Anaplastic Lymphoma Kinase Inhibitors Sales Market Share by Application in 2019
Figure 46. Southeast Asia Anaplastic Lymphoma Kinase Inhibitors Sales Market Share by Company in 2019
Figure 47. Southeast Asia Anaplastic Lymphoma Kinase Inhibitors Sales Market Share by Type in 2019
Figure 48. Southeast Asia Anaplastic Lymphoma Kinase Inhibitors Sales Market Share by Application in 2019
Figure 49. India Anaplastic Lymphoma Kinase Inhibitors Sales Market Share by Company in 2019
Figure 50. India Anaplastic Lymphoma Kinase Inhibitors Sales Market Share by Type in 2019
Figure 51. India Anaplastic Lymphoma Kinase Inhibitors Sales Market Share by Application in 2019
Figure 52. Betta Pharmaceutcials Co., Ltd. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 53. Crtierium, Inc. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 54. F.Hoffman-La Roche Ltd. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 55. Helsinn Therapeutics Total Revenue (US$ Million): 2019 Compared with 2018
Figure 56. Novartis AG. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 57. Oncoethix GmbH Total Revenue (US$ Million): 2019 Compared with 2018
Figure 58. Pfizer, Inc. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 59. Takeda Pharmaceutical Co., Ltd. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 60. Xcovery Holding Company, LLC Total Revenue (US$ Million): 2019 Compared with 2018
Figure 61. Tesaro, Inc. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 62. Key Raw Materials Price Trend
Figure 63. Manufacturing Cost Structure of Anaplastic Lymphoma Kinase Inhibitors
Figure 64. Manufacturing Process Analysis of Anaplastic Lymphoma Kinase Inhibitors
Figure 65. Anaplastic Lymphoma Kinase Inhibitors Industrial Chain Analysis
Figure 66. Channels of Distribution
Figure 67. Distributors Profiles
Figure 68. Porter's Five Forces Analysis
Figure 69. Bottom-up and Top-down Approaches for This Report
Figure 70. Data Triangulation
Figure 71. Key Executives Interviewed
未分化リンパ腫キナーゼ阻害剤の世界市場レポート2020 A recently published report by QY Research titled Global Anaplastic Lymphoma Kinase Inhibitors Sales Market Report 2020 is designed in a way that helps the readers to acquire a complete knowledge about the overall market scenario and it’s most lucrative sectors. The research report also statisticall…- ブルトン型チロシンキナーゼ（BTK）阻害剤の世界市場 2020年：メーカー別、地域別、種類・用途別 Market Overview The Bruton Tyrosine Kinase (BTK) Inhibitors market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value c…
- ブルトン型チロシンキナーゼ（BTK）阻害剤の世界市場 2020年：企業別、地域別、種類・用途別 Market Overview The Bruton's Tyrosine Kinase (BTK) Inhibitors market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value…
- クレアチンキナーゼ試薬の世界市場 2020年：メーカー別、地域別、種類・用途別 Market Overview The global Creatine Kinase Reagent market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Creatine Kinase Reage…
- クレアチンキナーゼ試薬の世界市場 2020年：メーカー別、地域別、種類・用途別 Market Overview The global Creatine Kinase Reagent market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Creatine Kinase Reage…